IL296380A - Therapeutic uses of l-4-chlorokynurenine - Google Patents

Therapeutic uses of l-4-chlorokynurenine

Info

Publication number
IL296380A
IL296380A IL296380A IL29638022A IL296380A IL 296380 A IL296380 A IL 296380A IL 296380 A IL296380 A IL 296380A IL 29638022 A IL29638022 A IL 29638022A IL 296380 A IL296380 A IL 296380A
Authority
IL
Israel
Prior art keywords
chlorokynurenine
depression
dose
diabetes
treatment
Prior art date
Application number
IL296380A
Other languages
English (en)
Hebrew (he)
Inventor
Ralph Snodgrass H
Original Assignee
Vistagen Therapeutics Inc
Ralph Snodgrass H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc, Ralph Snodgrass H filed Critical Vistagen Therapeutics Inc
Publication of IL296380A publication Critical patent/IL296380A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL296380A 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine IL296380A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562179924P 2015-05-22 2015-05-22
PCT/US2016/033733 WO2016191351A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Publications (1)

Publication Number Publication Date
IL296380A true IL296380A (en) 2022-11-01

Family

ID=57393671

Family Applications (3)

Application Number Title Priority Date Filing Date
IL296380A IL296380A (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine
IL255770A IL255770B (en) 2015-05-22 2017-11-20 Medicinal uses for l–4–chlorokynurenine
IL285882A IL285882A (en) 2015-05-22 2021-08-25 Medicinal uses for l–4–chlorokynurenine

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL255770A IL255770B (en) 2015-05-22 2017-11-20 Medicinal uses for l–4–chlorokynurenine
IL285882A IL285882A (en) 2015-05-22 2021-08-25 Medicinal uses for l–4–chlorokynurenine

Country Status (19)

Country Link
US (3) US20180140568A1 (2)
EP (2) EP4108239A1 (2)
JP (3) JP2018521007A (2)
KR (2) KR20180015158A (2)
CN (1) CN107949379A (2)
AU (3) AU2016268153B2 (2)
BR (1) BR112017024908A2 (2)
CA (1) CA3024783A1 (2)
DK (1) DK3297619T3 (2)
EA (1) EA201792571A1 (2)
ES (1) ES2925274T3 (2)
IL (3) IL296380A (2)
MX (1) MX395492B (2)
PL (1) PL3297619T3 (2)
PT (1) PT3297619T (2)
SG (1) SG10202007661XA (2)
SI (1) SI3297619T1 (2)
WO (1) WO2016191351A1 (2)
ZA (1) ZA201707874B (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3598971T (pt) 2013-01-22 2024-06-20 Vistagen Therapeutics Inc ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CA3136418A1 (en) * 2019-04-09 2020-10-15 Vistagen Therapeutics, Inc. Genetic variants associated with response to treatment of neurological disorders
JP7805969B2 (ja) * 2020-06-24 2026-01-26 バイオヘイブン・セラピューティクス・リミテッド 強迫性障害を治療するための組成物及び方法
WO2022221423A1 (en) * 2021-04-13 2022-10-20 Vistagen Therapeutics, Inc. Treatment of autoimmune anti-nmda-receptor encephalitis
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
WO2024011105A1 (en) * 2022-07-05 2024-01-11 Mahana Therapeutics, Inc. Methods and systems for treating tinnitus using digital therapeutics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AU2007235876A1 (en) * 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
WO2009061935A2 (en) * 2007-11-06 2009-05-14 Emory University Methods of identifying safe nmda receptor antagonists
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
KR20150096370A (ko) * 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
PT3598971T (pt) * 2013-01-22 2024-06-20 Vistagen Therapeutics Inc ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina
WO2014152835A1 (en) 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Synthesis of chiral kynurenine compounds and intermediates
CN107417558A (zh) 2013-03-14 2017-12-01 维斯塔津治疗公司 用于合成手性犬尿氨酸化合物的方法
KR20170013890A (ko) * 2014-05-06 2017-02-07 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물

Also Published As

Publication number Publication date
KR20240068766A (ko) 2024-05-17
EP3297619B1 (en) 2022-07-06
AU2023282234A1 (en) 2024-01-18
EA201792571A1 (ru) 2018-06-29
SG10202007661XA (en) 2020-09-29
US20180140568A1 (en) 2018-05-24
AU2021209279B2 (en) 2023-09-14
MX2017014456A (es) 2018-03-16
MX395492B (es) 2025-03-25
KR20180015158A (ko) 2018-02-12
IL255770B (en) 2021-09-30
JP2024050575A (ja) 2024-04-10
ES2925274T3 (es) 2022-10-14
US20240122887A1 (en) 2024-04-18
JP2022064908A (ja) 2022-04-26
AU2021209279A1 (en) 2021-08-19
CA3024783A1 (en) 2016-12-01
WO2016191351A1 (en) 2016-12-01
US20190321317A1 (en) 2019-10-24
EP3297619A4 (en) 2019-01-02
HK1257800A1 (en) 2019-11-01
EP3297619A1 (en) 2018-03-28
AU2016268153A1 (en) 2017-12-14
PL3297619T3 (pl) 2023-02-13
DK3297619T3 (da) 2022-08-15
JP2018521007A (ja) 2018-08-02
SI3297619T1 (sl) 2023-02-28
IL285882A (en) 2021-09-30
PT3297619T (pt) 2022-08-05
ZA201707874B (en) 2020-01-29
IL255770A (en) 2018-01-31
EP4108239A1 (en) 2022-12-28
BR112017024908A2 (pt) 2018-07-31
CN107949379A (zh) 2018-04-20
AU2016268153B2 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
JP7532021B2 (ja) ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物
Winblad et al. Therapeutic use of nicergoline
AU2024203022A1 (en) LSD dose identification
KR20140041670A (ko) 행동 장애 및 정신 장애의 치료를 위한 실로―이노시톨
IL276126A (en) Compositions comprising l-4-chlorokynurenine and uses thereof
JP2024519866A (ja) 神経学的疾患を治療するための方法及び組成物
KR102776048B1 (ko) 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물
Zhang et al. Progress of non‐motor symptoms in early‐onset Parkinson's disease
WO2020068913A1 (en) Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases
MD3897578T2 (ro) Regimuri de dozare pentru utilizarea LY3154207 în tratamentul tulburărilor dopaminergice ale SNC
JP2024507492A (ja) 精神療法を補助するためのメスカリン及びメスカリン類似体（スカリン）の効果
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine
US20260083740A1 (en) Use of tavapadon in treating parkinson's disease
AU2017387713A1 (en) Variants of 2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid for use in the treatment, prevention and/or amelioration of brain diseases
HK40060568A (en) Domperidone antineurodegenerative combinations and use
CN113365629A (zh) 多潘立酮抗神经退行性组合物及用途
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain
DellaMarca andAlbertoAlbanese 10 sleep-related disorders